Human iPSC-CMs and in-silico technologies define mechanisms and accelerate targeted pharmacogenetics in hypertrophic cardiomyopathy
F. Margara, Y. Psaras, Z. J. Wang, M. Schmid, R. Doste, A. Garfinkel, G. G. Repetti, J. Seidman, C. Seidman, B. Rodriguez, C. N. Toepfer, A. Bueno-Orovio
The paper combines human iPSC-CMs and in-silico models to identify genotype-specific pathomechanisms and therapeutic targets in hypertrophic cardiomyopathy.
bioRxiv · Jun 8, 2022 · PreprintBioengineering